Endocrine| Volume 169, ISSUE 5, P1152-1157, May 2021

The effect of chronic kidney disease on intraoperative parathyroid hormone: A linear mixed model analysis

Published:January 07, 2021DOI:



      Reduced creatinine clearance is an indication for surgery in asymptomatic primary hyperparathyroidism, and a significant proportion of patients undergoing parathyroidectomy have chronic kidney disease. The purpose of this study was to evaluate the kinetics of intraoperative parathyroid hormone decline during parathyroidectomy in patients who have chronic kidney disease compared with those with who have normal renal function.


      This is a single-center, retrospective study of patients with primary hyperparathyroidism undergoing parathyroidectomy (n = 646). Patients were grouped based on estimated glomerular filtration rate greater than (normal renal function) or less than (chronic kidney disease) 60 mL/min/1.73m2. All patients had intraoperative parathyroid hormone monitoring and ≥6-month postoperative serum studies to confirm surgical cure. Intraoperative parathyroid hormone kinetic curves were analyzed using a linear mixed model.


      Despite similar pre-excision values, patients with chronic kidney disease had significantly higher intraoperative parathyroid hormone values at 5 minutes (76 vs 58 pg/mL, P = .02) and 10 minutes (54 vs 37 pg/mL, P = .004) postexcision. No significant difference was observed in whether patients met Miami criterion by 5 minutes (chronic kidney disease 71%, normal renal function 78%, P = .255) or by 10 minutes (chronic kidney disease 95%, normal renal function 96%, P = .751) postexcision. Using a linear mixed model, glomerular filtration rate did not have a significant effect on the change in intraoperative parathyroid hormone over time.


      Patients with chronic kidney disease had significantly higher postexcision intraoperative parathyroid hormone levels. However, renal function did not affect the change in intraoperative parathyroid hormone over time, nor did renal function ultimately affect the likelihood of meeting the Miami criterion. Intraoperative parathyroid hormone monitoring remains useful in this population, although additional time points may be needed to observe normalization of values.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Wilhelm S.M.
        • Wang T.S.
        • Ruan D.T.
        • et al.
        The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism.
        JAMA Surg. 2016; 151: 959-968
        • Walker M.D.
        • Silverberg S.J.
        Primary hyperparathyroidism.
        Nat Rev Endocrinol. 2018; 14: 115-125
        • Pasieka J.L.
        • Parsons L.
        • Jones J.
        The long-term benefit of parathyroidectomy in primary hyperparathyroidism: a 10-year prospective surgical outcome study.
        Surgery. 2009; 146: 1006-1013
        • Marcadis A.R.
        • Teo R.
        • Ouyang W.
        • Farrá J.C.
        • Lew J.I.
        Successful parathyroidectomy guided by intraoperative parathyroid hormone monitoring for primary hyperparathyroidism is preserved in mild and moderate renal insufficiency.
        Surgery. 2018; 163: 633-637
        • Bilezikian J.P.
        • Brandi M.L.
        • Eastell R.
        • et al.
        Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop.
        J Clin Endocrinol Metab. 2014; 99: 3561-3569
        • Tassone F.
        • Guarnieri A.
        • Castellano E.
        • Baffoni C.
        • Attanasio R.
        • Borretta G.
        Parathyroidectomy halts the deterioration of renal function in primary hyperparathyroidism.
        J Clin Endocrinol Metab. 2015; 100: 3069-3073
        • Nair C.G.
        • Babu M.
        • Jacob P.
        • Menon R.
        • Mathew J.
        • Unnikrishnan
        Renal dysfunction in primary hyperparathyroidism; effect of parathyroidectomy: a retrospective cohort study.
        Int J Surg. 2016; 36: 383-387
        • Greene A.B.
        • Butler R.S.
        • McIntyre S.
        • et al.
        National trends in parathyroid surgery from 1998 to 2008: a decade of change.
        J Am Coll Surg. Published online. 2009; 209: 332-343
        • Reeve T.S.
        • Babidge W.J.
        • Parkyn R.F.
        • et al.
        Minimally invasive surgery for primary hyperparathyroidism: a systematic review.
        Aust N Z J Surg. Published online. 2000; 70: 244-250
        • Carneiro D.M.
        • Solorzano C.C.
        • Nader M.C.
        • et al.
        Comparison of intraoperative iPTH assay (QPTH) criteria in guiding parathyroidectomy: which criterion is the most accurate?.
        Surgery. 2003; 134 (discussion 979–981): 973-979
        • Irvin G.L.
        • Solorzano C.C.
        • Carneiro D.M.
        Quick intraoperative parathyroid hormone assay: surgical adjunct to allow limited parathyroidectomy, improve success rate, and predict outcome.
        World J Surg. 2004; 28: 1287-1292
        • Patel K.N.
        • Caso R.
        Intraoperative parathyroid hormone monitoring. Optimal utilization.
        Surg Oncol Clin N Am. 2016; 25: 91-101
        • Martin K.J.
        • Hruska K.A.
        • Freitag J.J.
        • Klahr S.
        • Slatopolsky E.
        The peripheral metabolism of parathyroid hormone.
        N Engl J Med. 1979; 301: 1092-1098
        • Helbrow J.
        • Owais A.E.
        • Sidwell A.G.
        • Frank L.M.
        • Lucarotti M.E.
        The use of intraoperative parathyroid hormone monitoring in minimally invasive parathyroid surgery.
        Ann R Coll Surg Engl. 2016; 98: 516-519
        • Leiker A.J.
        • Yen T.W.F.
        • Eastwood D.C.
        • et al.
        Factors that influence parathyroid hormone half-life: determining if new intraoperative criteria are needed.
        JAMA Surg. 2013; 148: 602-606
        • Gannagé-Yared M.H.
        • Abboud B.
        • Amm-Azar M.
        • et al.
        Predictors of intra-operative parathyroid hormone decline in subjects operated for primary hyperparathyroidism by minimally invasive parathyroidectomy.
        J Endocrinol Invest. 2009; 32: 160-164
        • Graves C.E.
        • McManus C.M.
        • Chabot J.A.
        • Lee J.A.
        • Kuo J.H.
        Vitamin D does not affect intraoperative parathyroid hormone kinetics: a mixed linear model analysis.
        J Surg Res. 2019; 241: 199-204
        • Sohn J.A.
        • Oltmann S.C.
        • Schneider D.F.
        • Sippel R.S.
        • Chen H.
        • Elfenbein D.M.
        Is intraoperative parathyroid hormone testing in patients with renal insufficiency undergoing parathyroidectomy for primary hyperparathyroidism accurate?.
        Am J Surg. 2015; 209: 483-487
        • Sunkara B.
        • Cohen M.S.
        • Miller B.S.
        • Gauger P.G.
        • Hughes D.T.
        Influence of concurrent chronic kidney disease on intraoperative parathyroid hormone monitoring during parathyroidectomy for primary hyperparathyroidism.
        Surgery. 2018; 163: 42-47
        • Egan R.J.
        • Iliff H.
        • Stechman M.J.
        • Scott-Coombes D.M.
        Intraoperative parathyroid hormone assay remains predictive of cure in renal impairment in patients with single parathyroid adenomas.
        World J Surg. 2018; 42: 2835-2839
        • Liu S.N.
        • Yusufali A.H.
        • Mao M.L.
        • Khan Z.F.
        • Farrá J.C.
        • Lew J.I.
        Stricter ioPTH criterion for successful parathyroidectomy in stage III CKD patients with primary hyperparathyroidism.
        Surgery. 2018; 164: 1306-1310
        • Shawky M.S.
        • Sakr M.F.
        • Nabawi A.S.
        • et al.
        Influence of common clinical variables on intraoperative parathyroid hormone monitoring during surgery for primary hyperparathyroidism.
        J Endocrinol Invest. 2020; 43: 1205-1212
        • Bishop B.
        • Wang B.
        • Parikh P.P.
        • Lew J.I.
        Intraoperative parathormone monitoring mitigates age-related variability in targeted parathyroidectomy for patients with primary hyperparathyroidism.
        Ann Surg Oncol. 2015; 22: S655-S661
        • Goldfarb M.
        • Singer F.R.
        Recent advances in the understanding and management of primary hyperparathyroidism.
        F1000Research. 2020; 9: 143
        • Graves C.E.
        • McManus C.M.
        • Chabot J.A.
        • Lee J.A.
        • Kuo J.H.
        Biochemical profile affects IOPTH kinetics and cure rate in primary hyperparathyroidism.
        World J Surg. 2020; 44: 488-495
        • Trinh G.
        • Rettig E.
        • Noureldine S.I.
        • et al.
        Surgical management of normocalcemic primary hyperparathyroidism and the impact of intraoperative parathyroid hormone testing on outcome.
        Otolaryngol Head Neck Surg. 2018; 159: 630-637
        • Trinh G.
        • Noureldine S.I.
        • Russell J.O.
        • et al.
        Characterizing the operative findings and utility of intraoperative parathyroid hormone (IOPTH) monitoring in patients with normal baseline IOPTH and normohormonal primary hyperparathyroidism.
        Surgery. 2017; 161: 78-86
        • Siperstein A.E.
        • Shen W.
        • Chan A.K.
        • Duh Q.Y.
        • Clark O.H.
        Normocalcemic hyperparathyroidism: biochemical and symptom profiles before and after surgery.
        Arch Surg. 1992; 127 (discussion 1161–1163): 1157-1161
        • Traini E.
        • Bellantone R.
        • Tempera S.E.
        • et al.
        Is parathyroidectomy safe and effective in patients with normocalcemic primary hyperparathyroidism?.
        Langenbecks Arch Surg. 2018; 403: 317-323
        • Cusano N.E.
        • Cipriani C.
        • Bilezikian J.P.
        Management of normocalcemic primary hyperparathyroidism.
        Best Pract Res Clin Endocrinol Metab. 2018; 32: 837-845
        • Orr L.E.
        • McKenzie T.J.
        • Thompson G.B.
        • Farley D.R.
        • Wermers R.A.
        • Lyden M.L.
        Surgery for primary hyperparathyroidism with normal non-suppressed parathyroid hormone can be both challenging and successful.
        World J Surg. 2018; 42: 409-414
        • Lepage R.
        • Roy L.
        • Brossard J.H.
        • et al.
        A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples.
        Clin Chem. 1998; 44: 805-809
        • Smit M.A.
        • van Kinschot C.M.J.
        • van der Linden J.
        • van Noord C.
        • Kos S.
        Clinical guidelines and PTH measurement: does assay generation matter?.
        Endocr Rev. 2019; 40: 1468-1480
        • Yamashita H.
        • Gao P.
        • Cantor T.
        • et al.
        Comparison of parathyroid hormone levels from the intact and whole parathyroid hormone assays after parathyroidectomy for primary and secondary hyperparathyroidism.
        Surgery. 2004; 135: 149-156
        • Lang B.H.
        • Fung M.M.H.
        Intraoperative parathyroid hormone (IOPTH) assay might be better than the second-generation assay in parathyroidectomy for primary hyperparathyroidism.
        Surgery. 2021; 169: 109-113